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Recent studies indicate that SIRT1, an important metabolic sensor and regulator of lifespan, plays a 26 
mechanistic role in maternal obesity-induced programming of metabolic disorders in the offspring. 27 
In this study we investigate whether SIRT1 activation in early childhood can mitigate metabolic 28 
disorders due to maternal and postnatal high-fat feeding in mice. Male offspring born to chow-fed 29 
(MC) or high-fat diet-fed dams (MHF) were weaned onto postnatal chow or high-fat diet and 30 
treated with SRT1720 (SRT, 25mg/kg/2days i.p) or vehicle control (VEH) for 6 weeks and 31 
examined for metabolic disorders. MHF exacerbated offspring body weight and insulin resistance 32 
in the offspring exposed to postnatal HFD (OHF). These metabolic changes were associated with 33 
reduced hepatic lipid droplet accumulation but increased plasma levels of alanine aminotransferase 34 
(ALT), a marker of liver damage. SRT1720 significantly decreased offspring body weight, 35 
adiposity, glucose intolerance, hyperleptinemia due to OHF, and reversed hyperinsulinemia and 36 
adipocyte hypertrophy due to the additive effects of MHF. Although SRT1720 suppresses liver 37 
lipogenesis, inflammation and oxidative stress markers, it also reduces antioxidants and increased 38 
liver collagen deposition in OHF offspring independent of MHF. Hepatic steatosis was attenuated 39 
only in MC/OHF offspring in association with elevated plasma ALT levels. The study suggests 40 
postnatal SRT1720 administration can mitigate obesity and insulin resistance in the offspring due 41 
to maternal and postnatal HFD exposure. However, the possibility of liver toxicity needs to be 42 




It is well-established that unhealthy parental lifestyles and related diseases such as obesity and 47 
diabetes can increase the risk of metabolic disorders in the offspring (13, 18). Specifically, an 48 
unbalanced diet such as high fat and high simple carbohydrate before and during pregnancy can 49 
predispose the offspring to childhood obesity and metabolic disorders such as diabetes and non-50 
alcoholic fatty liver disease (NAFLD) through epigenetic and metabolic programming due to 51 
various factors such as overnutrition, oxidative stress and inflammation (2, 5, 16, 29). Importantly, 52 
the effects cannot be reversed by conventional approaches such as weight gain management during 53 
pregnancy (4). As such, investigation of alternative approaches has become imperative. 54 
 55 
Sirtuin (SIRT)1 is an essential metabolic and lifespan regulating factor (12). Its expression and 56 
activity are dependent on the cellular availability of NAD
+
, an energy carrier whose level is 57 




-precursors has been shown to mimic the effects of caloric restriction on obesity 59 
and lifespan in animals (6, 14, 24). At the molecular level, SIRT1 activation leads to suppression of 60 
de novo lipogenesis (DNL) regulators including peroxisome proliferator-activated receptor gamma 61 
(PPARγ), sterol regulatory element-binding protein (SREBP-1c), fatty acid synthase (FASN), while 62 
boosting lipolysis markers such as peroxisome PPARγ-coactivator α (PGC-1α) and PPARα (12, 23). 63 
SIRT1 also positively regulates antioxidant enzymes and prevents oxidative stress (1). However, 64 
the effects of SIRT1 therapeutics in the context of maternal obesity are yet to be elucidated (23). 65 
 66 
Multiple studies have demonstrated reduced SIRT1 expression in the placenta (27), oocyte (7), 67 
fetus (30), and neonatal tissue (22) due to maternal aging or high-fat diet (HFD) consumption, 68 
suggesting the relevance of SIRT1 in fetal programming (23). Particularly, our recent unpublished 69 
data demonstrated that SIRT1-transgenic mice born to obese dams have decreased body weight, 70 
adiposity, glucose intolerance and insulin resistance compared to Wild-type littermates at weaning, 71 
providing a proof of concept for SIRT1 therapeutics during early developmental periods to 72 
counteract the transgenerational effects of maternal obesity. The study is to further examine the 73 
hypothesis by administration of SRT1720, a potent STAC with well-established anti-diabetic 74 
effects in animals (21), in the offspring exposed to maternal and postnatal HFD in adolescence. 75 
 76 
MATERIALS AND METHODS  77 
 78 
Animals  79 
The study was approved by the Animal Care and Ethics Committee of the University of Sydney 80 
(RESP/15/22). All procedures were performed in accordance with the relevant guidelines and 81 
regulations in the Australian Code of Practice for the Care and Use of Animals for Scientific 82 
Purposes. All mice were housed at the Kearns Animal Facility at the Kolling Institute, Royal North 83 
Shore Hospital. The animals were maintained at 22 ± 1°C with a 12/12 hour light to dark cycle, and 84 
monitored at least once per fortnight.  Female C57BL/6 mice (8 weeks) were fed a high-fat diet 85 
(HFD, 20 kJ/g, 43.5% calorie as fat, Specialty Feed, WA, Australia) or standard rodent chow (11 86 
kJ/g, 14% calorie as fat, Gordon’s Speciality Stockfeeds, NSW, Australia) for 6 weeks before 87 
mating, throughout gestation and lactation (11, 22). On postnatal day (P) 1, female mice were 88 
culled and male mice were adjusted to 4-6 pups/ litter. At weaning (P20), the offspring were 89 
weaned on Chow or HFD and treated with SRT1720 (25mg/kg/2days i.p) for 6 weeks. At week 9, 90 
the offspring were sacrificed. Blood was collected via cardiac puncture after anaesthesia (Pentothal, 91 
0.1mg/g, i.p., Abbott Australasia Pty Ltd, NSW, Australia). Phosphate-buffered saline (PBS, 1%) 92 
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was used for whole body perfusion. Tissues were snapped frozen and stored at −80 °C or fixed in 93 
Neutral buffered formalin (10%) for approximately 36h for later analyses. 94 
 95 
Intraperitoneal glucose tolerance test (IPGTT)  96 
At week 9, the animals were weighed and fasted for 5h prior to IPGTT, then a glucose solution 97 
(50%) was injected (2g/kg, i.p.). Tail blood glucose level was recorded prior to glucose injection at 98 
15, 30, 60 and 90min post injection using a glucometer (Accu-Chek glucose meter; Roche 99 
Diagnostics) (13). The area under the curve (AUC) was calculated for each animal.  100 
 101 
Protein and lipid extraction from tissues  102 
The tissues were homogenized in Triton X-100 lysis buffer (pH 7.4, 150 mM NaOH, 50 mM Tris-103 
HCl, 1% Triton X-100, Roche protease inhibitor) using TissueRuptor (Qiagen, Hilden, Germany). 104 
Lipid and protein was extracted and measured for concentrations according to our previously 105 
published protocol (14) using Roche triglyceride reagent GPO-PAP (Roche Life Science, NSW, 106 
Australia) and Pierce BCA Protein Assay Kit (Thermo Scientific, VIC, Australia) according to the 107 
manufacturer’s instructions. Lipid concentrations were normalised to the protein concentration. 108 
 109 
Quantitative RT-PCR  110 
Total RNA of liver tissues was isolated using RNeasy Plus Mini Kit (Qiagen Pty Ltd, CA, USA) 111 
according to the manufacturer’s instructions, while RNA of fat tissues was extracted using Trizol 112 
Reagent (Sigma-Aldrich). The purified total RNA was used as a template to generate first-strand 113 
cDNA using the First Strand cDNA Synthesis Kit (Roche Life Science, NSW, Australia). The 114 
amplicons of target genes were amplified with SYBR Green probes. Primer sequences were 115 
summarised in Table 1. Gene expression was standardized to β-actin mRNA. 116 
 117 
Histology  118 
Tissues were fixed in 10% formalin for 36-h and embedded in paraffin or frozen-embedded in OCT 119 
solution (Tissue-Tek). Paraffin sections were prepared at 4 μm thickness and mounted on 120 
microscope slides. The sections were stained with hematoxylin and eosin (H&E) for general 121 
structural visualisation. For adipocyte frequency analysis, H&E-stained paraffin sections were 122 
observed using bright-field microscope (Leica Microsystems, Germany) and 6 random non-123 
overlapping fields were captured at 200X magnification. Adipocyte size analysis was done by 124 
Adiposoft software (9).  125 
 126 
 5 
Hepatic steatosis was assessed by both H&E and Oil Red O (ORO) staining. In ORO staining, 127 
frozen tissues were sectioned at 12 μm thickness, briefly fixed in Neutral buffered formalin (10%), 128 
stained with Oil Red O (ORO, Sigma-Aldrich, MO, USA) working solution (3g in 60% 129 
isopropanol) for 15 mins, differentiated in 60% isopropanol and distilled water, and counter-stained 130 
with Mayer’s haematoxylin for 15s. For liver collagen staining, paraffin sections were stained with 131 
Fast Green for 30 mins followed by rinsing in water and incubation in Picro-Sirius Red (PSR) for 132 
another 30 mins.  133 
 134 
Alanine aminotransferase assay 135 
The Alanine Transaminase Colorimetric Activity Assay was performed as per instructions by the 136 
manufacturer (Cayman, USA). 137 
 138 
Statistical analysis 139 
The data were analysed by two-way ANOVA followed by Bonferroni post hoc tests. P<0.05 is 140 




SRT1720 attenuated body weight and adiposity in offspring born to HFD-fed dams 145 
Consistent with previous studies, offspring fed a postnatal HFD showed increased body weight 146 
(P<0.001, Figure 1B). Caloric intake showed a trend to increase in this group but was not 147 
significantly different from the control after adjustment to body weight (Figure 1D). In association, 148 
epididymal and retroperitoneal fat mass, as well as the plasma levels of triglyceride, non-esterified 149 
fatty acid and leptin were also augmented (P<0.01) (Figure 1C and 1E). Maternal HFD 150 
consumption (MHF) significantly increased body weight of HFD-fed offspring (OHF) at week 9 151 
(P<0.01, Figure 1B), and further increased the offspring’s caloric intake to a significant level (P < 152 
0.01 vs MC/OC/V, Figure 1D). Plasma leptin levels also showed a trend of increase (P=0.06). No 153 
additive effects of MHF on OHF offspring adiposity and hyperlipidemia were seen. 154 
 155 
SRT1720 administration significantly reduced body weight, white adipose tissue (WAT) mass and 156 
leptin levels in OHF offspring born to either chow or HFD-fed mothers (Figure 1B, 1C and 1E). 157 
Together with slightly increased caloric intake (Figure 1D), the results suggest improved energy 158 
expenditure. The treatment had no effect on hyperlipidemia due to HFD exposure (Figure 1E).   159 
 160 
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SRT1720 attenuated glucose intolerance and insulin resistance in offspring born to HFD-fed 161 
dams 162 
Glucose tolerance was significantly impaired in MC/OHF offspring (P<0.001, Figure 2A and 2B). 163 
However, plasma insulin levels and the insulin resistance index (HOMA-IR) remained unchanged 164 
in this group. Hyperinsulinemia and insulin resistance was significantly increased only in those 165 
OHF offspring pre-exposed to MHF (P<0.01 and P<0.05 respectively in comparison to MC/OC) 166 
(Figure 2C and 2D).  167 
 168 
SRT1720 administration significantly improved glucose tolerance in HFD-exposed offspring 169 
(P<0.01), and normalised hyperinsulinemia and insulin resistance in those pre-exposed to MHF 170 
(P<0.05 and P=0.07 respectively). Further mRNA expression analysis in offspring RpWAT 171 
revealed a similar trend in the regulation of insulin receptors to plasma insulin. 172 
 173 
SRT1720 suppressed adipocyte hypertrophy and lipogenesis 174 
Despite having no additive effects on offspring WAT mass, MHF significantly amplified adipocyte 175 
size (P<0.05 vs MC/OHF, Figure 3B). The mRNA expression of SREBP-1c was slightly but not 176 
significantly suppressed by postnatal HFD (P=0.054), whilst UCP1 showed a trend to increase 177 
(Figure 3C). The mRNA expression of uncoupling protein UCP2 was also significantly upregulated 178 
by OHF (P<0.01). MHF had no additive effects on the regulation of these markers (Figure 3C).  179 
 180 
SRT1720 administration significantly suppressed the expression of the lipogenesis markers PPARγ 181 
in both MC/OHF and MHF/OHF offspring (P<0.05 and P<0.01 respectively, Figure 3C). Similarly, 182 
FASN was downregulated by SRT1720 in MC/OHF offspring only (P<0.05) and SREBP-1c 183 
showed a tendency of suppression in MHF/OHF/S group (P=0.064). No significant alternations in 184 
UCP1 mRNA expression were found between vehicle and SRT1720-treated groups despite a trend 185 
of normalisation in MC/OHF offspring. UCP2 was significantly increased by the treatment but in 186 
MC/OC offspring only (P<0.01). 187 
 188 
The effects of MHF and SRT1720 on lipid deposition in offspring liver 189 
Liver triglyceride contents were significantly increased in OHF offspring independent of MHF 190 
(P<0.01, Figure 4A). Lipid droplet accumulation, reflected by H&E and ORO staining, was also 191 
increased in OHF offspring (P<0.001, Figure 4B, 4C). Surprisingly, the increase was significantly 192 
suppressed in those pre-exposed to MHF (P<0.01, Figure 4B, 4C). The expression of SREBP-1c, a 193 
marker of liver lipotoxicity, was similarly upregulated in both HFD-exposed groups (P<0.01 and 194 
P<0.05 respectively, Figure 4D). In contrast, the cholesterol regulator Liver X receptor β (LXRβ) 195 
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showed a trend to downregulation by HFD. MHF slightly exacerbated the reduction of LXRβ in the 196 
offspring (P<0.05 vs MC/OC). In contrast, the protein expression of phosphorylated AMP-197 
activated protein kinase (AMPK) tended to decrease in the presence of maternal HFD (Figure 4E). 198 
No change in the expression of total AMPK and PGC-1α was found. 199 
 200 
SRT1720 decreased the level of lipid accumulation in MC/OHF offspring only, as reflected by liver 201 
TG (n.s), H&E staining, and ORO staining (P<0.001). These changes were associated with reduced 202 
mRNA expression of SREBP-1c in all groups (all P<0.01), FASN and carbohydrate-responsive 203 
element-binding protein (ChREBP) in MC/OHF and MHF/OHF offspring (all P<0.05). 204 
Interestingly, PPARγ expression was suppressed by SRT1720 only in MC/OHF offspring (P<0.05) 205 
(Figure 4D). In association, there was a trend of increase in the protein expression of pAMPK 206 
(Figure 4E). 207 
  208 
SRT1720 regulated liver oxidative stress, inflammation, and liver damage in a diet-dependent 209 
manner 210 
The expression of NADPH oxidase (NOX)2 mRNA was slightly but not significantly increased 211 
(P=0.09) in MHF/OHF offspring (Figure 5A), suggesting increased reactive oxygen species (ROS) 212 
production and potential oxidative damage. Antioxidant enzymes Glutathione Peroxidase (GPx)-1 213 
and catalase (CAT) showed similar trends of reduction in OHF offspring (Figure 5A). 214 
Inflammatory marker tumour necrosis factor (TNF)α, macrophage and microglial marker F4/80, 215 
and pro-apoptotic/endoplasmic reticulum stress marker C/EBP homologous protein (CHOP) were 216 
not significantly regulated by postnatal or maternal HFD exposure (Figure 5A). Postnatal and 217 
maternal HFD also did not alter mRNA expression of collagen type IV (COL4) and fibronectin (FN) 218 
(Figure 5B) but led to a trend to increase in collagen protein expression as reflected by PSR 219 
staining (Figure 5C). The plasma level of alanine aminotransferase (ALT), a marker of liver 220 
damage, was increased only in the MHF/OHF group (P<0.05 vs MC/OC, Figure 5D). 221 
 222 
SRT1720 administration consistently improved the levels of TNFα, SOD1, SOD2, GPx-1, CAT 223 
and NOX2 in control offspring, but suppressed the mRNA expression of these markers in those 224 
exposed to HFD (Figure 5A, 5B). The data suggests that the effects of SRT1720 on inflammation 225 
and oxidative stress are diet-dependent. SRT1720 significantly increased mRNA expression of 226 
COL4 and FN (P<0.05) and PSR staining (P<0.05) in both offspring groups exposed to HFD 227 






Here we show that maternal high-fat diet consumption can increase body weight, adipocyte 233 
hypertrophy and insulin resistance in the offspring postnatally exposed to high-fat diet. MHF is also 234 
associated with a lower level of hepatic lipid droplet accumulation but higher level of liver damage. 235 
SRT1720 administration after weaning in the offspring suppressed their weight gain, adipocyte 236 
hypertrophy and hyperinsulinemia due to postnatal and maternal HFD.  237 
 238 
It is noteworthy that maternal HFD did not exacerbate the effects of postnatal HFD feeding on 239 
offspring adiposity at 9 weeks of age, which is at variance with our previous data in a rat model at 240 
the same age (10), suggesting that mice are less susceptible to maternal HFD-induced 241 
developmental programming of abnormal fat deposition. This is potentially due to the more active 242 
lifestyle of mice compared with rats. Despite the lack of difference in fat mass due to MHF, which 243 
has been shown to persist till week 32 of age (11), MHF induced adipocyte hypertrophy in the 244 
offspring, which has also been regarded as an important contributor to insulin resistance (32). 245 
Indeed, in this study, MHF is associated with hyperinsulinemia and increased HOMA-IR index in 246 
the offspring at week 9. Glucose tolerance is not exacerbated by maternal HFD at this time point 247 
but later in adulthood (11). These results suggest MHF predisposes OHF offspring to insulin 248 
resistance and exacerbates glucose intolerance later in life.  249 
 250 
In association with increased insulin, MHF also led to increased plasma leptin levels in OHF 251 
offspring. As leptin is primarily produced by adipocytes, the increased adipocyte size due to MHF 252 
is likely to underline this effect. The inhibition effect of SRT1720 on offspring hyperleptinaemia is 253 
consistent with the reduced fat mass and adipocyte hypertrophy. SRT1720 suppressed the 254 
expression of lipogenesis markers PPARγ, SREBP-1c and FASN, particularly in HFD-exposed 255 
offspring WAT, which supports reduced fat mass and smaller adipocyte size. The increases of 256 
UCP1 and UCP2 are consistent with previous studies in HFD-fed animals (8, 28), and are likely to 257 
reflect compensatory pathways for energy homeostasis. 258 
 259 
With respect to liver outcomes, offspring of chow-fed dams that are exposed to HFD after weaning 260 
have increased liver lipogenesis and steatosis but normal plasma ALT levels. In comparison, HFD-261 
fed offspring of HFD-fed dams have the same level of liver triglyceride but reduced steatosis and 262 
elevated ALT. The mechanism for the discrepancy between triglyceride and steatosis levels is 263 
unknown; however, we can postulate that not all triglycerides molecules were packed in the form 264 
of lipid droplets in the liver of these offspring. This may imply a disorder in hepatic lipid 265 
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mobilization due to maternal HFD. The result also suggests that it is not only the amount of lipid 266 
but also the form of lipid can contribute to liver injury. Indeed, it has been recently shown that free 267 
fatty acids, not triglycerides, are associated with progression of NAFLD in diet-induced obese rats 268 
(19). Moreover, the inhibition of triglyceride synthesis may improve hepatic steatosis but 269 
exacerbate liver oxidative damage and remodelling in obese mice (33). This is likely to explain 270 
why in our study, SRT1720-induced suppression of liver lipogenesis markers (PPARγ, FASN, 271 
ChREBP) and lipid droplet accumulation in HFD-fed offspring is associated with reduced levels of 272 
antioxidants and increased levels of liver fibrosis and injury markers. Consistent with the study by 273 
Yamaguchi (33), these negative effects occur despite reduced expression of ROS production and 274 
inflammation markers and improved systemic insulin sensitivity. It is also noteworthy that the 275 
negative effects of SRT1720 on fibrogenesis have been reported in several studies in different 276 
tissues (15, 26, 34) alongside with the benefits on metabolism. 277 
 278 
High levels of suppression of de novo lipogenesis pathways in WAT can also lead to liver injuries 279 
in SRT1720-administrated offspring. SRT1720 suppresses WAT expression of PPARγ, which has 280 
been shown to disrupt adipogenesis-associated lipid storage and lead to lipotoxicity in peripheral 281 
tissues including liver (20).  Activation of PPARγ, on the other hand, has been shown to result in 282 
lower body weight, visceral WAT and plasma triglyceride in the offspring born to HFD-fed 283 
mothers (17), which is likely to be associated with improved liver outcomes. 284 
 285 
In contrast to other studies (3), the SIRT1-AMPK-PGC-1α pathway appear to play a limited role in 286 
the current model. Therefore, we believe that the effects of SRT1720 are mainly mediated via the 287 
regulation of lipogenesis markers including SREBP-1c and PPARγ. Supporting this hypothesis, it 288 
has been shown that SIRT1 can repress the expression of SREBP-1c and PPARγ as well as their 289 
downstream markers such as FASN (25, 31). 290 
 291 
In conclusion, the study supports the use of SIRT1 agonists in the offspring at early ages to 292 
ameliorate the transgenerational effects of maternal obesity on systemic metabolism homeostasis of 293 
lipid and glucose. It is also clinically important that SRT1720 administration overall does not result 294 
in significant metabolic and liver changes in the control offspring. However, the side effects of the 295 
therapy on the liver in HFD-exposed offspring need to be further examined. 296 
 297 
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Table 1. RT-PCR primer sequences.  413 
 414 
No. Gene Forward primer sequence Reverse primer sequence 
1 Actin CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 
2 CAT CTCCATCAGGTTTGTTTCTTG CAACAGGCAAGTTTTTGATG 
3 CHOP CCACCACACCTGAAAGCAGA AGGCGAAAGGCAGAGACTCA 
4 ChREBP ATATCTCCGACACACTCTTC CAACATAAGCATCTTCTGGG 
5 COL1A CATGTTCAGCTTTGTGGACCT   GCAGCTGACTTCAGGGATGT   
6 COL3A TCCCCTGGAATCTGTGAATC TGAGTCGAATTGGGGAGAAT 
7 COL4 AAGGACTCCAGGGACCAC CCCACTGAGCCTGTCACAC 
8 F4/80 CCTGGACGAATCCTGTGAAG GGTGGGACCACAGAGAGTTG 
9 FASN TGCTCCCAGCTGCAGGC GCCCGGTAGCTCTGGGTGTA 
10 FN CGGAGAGAGTGCCCCTACTA CGATATTGGTGAATCGCAGA 
11 GPX1 GGACAATGGCAAGAATGAAG TTCGCACTTCTCAAACAATG 
12 InsR TTTGTCATGGATGGAGGCTA   CCTCATCTTGGGGTTGAACT   
13 LXRB TCACCCACTATTAAGGAAGAG TCTAAGATGACCACGATGTAG 
14 NOX2 CTACCTAAGATAGCAGTTGATG TACCAGACAGACTTGAGAATG 
15 PGC1A AAACTTGCTAGCGGTCCTCA TGGCTGGTGCCAGTAAGAG 
16 PPARG ATCTACACGATGCTGGC GGATGTCCTCGATGGG 
17 SIRT1 GCAGGTTGCGGGAATCCAA GGCAAGATGCTGTTGCAAA 
18 SOD1 CACTCTAAGAAACATGGTGG GATCACACGATCTTCAATGG 
19 SOD2 GGCCTACGTGAACAACCTGAA CTGTAACATCTCCCTTGGCCA 
20 SREBP-1c GGAGCCATGGATTGCACATT GCTTCCAGAGAGGAGGCCAG 
21 TNF-a CTGTAGCCCACGTCGTAGC TTGAGATCCATGCCGTTG 
22 UCP1 CTTTTTCAAAGGGTTTGTGG CTTATGTGGTACAATCCACTG 
23 UCP2 ACCTTTAGAGAAGCTTGACC TTCTGATTTCCTGCTACCTC 
  415 
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FIGURE LEGENDS 416 
Figure 1. Experiment design, anthropometric data and blood analysis. A. Experiment design; B. 417 
Offspring body weight (n = 9 – 17); C. Fat mass (n = 9 – 17); D. Caloric intake (n = 9 – 15); E. 418 
Plasma levels of Non-Esterified Fatty Acid, Triglyceride and leptin. (n = 7 – 8). Data are presented 419 
as mean ± SEM. Vs MC/OC/V (*p < 0.05, **p < 0.01, ***p < 0.001); vs MC/OHF/V (‡‡p < 0.01); 420 
SRT1720-treatment group vs the corresponding VEH-treated controls (†p < 0.05††p < 0.01, †††p < 421 
0.01) 422 
  423 
Figure 2. Offspring glucose tolerance and insulin sensitivity. A. Intraperitoneal glucose tolerance 424 
test and B. Area under the curve (n = 7 – 15). C. Plasma insulin level and D. Homeostatic model 425 
assessment of insulin resistance (n = 3 - 5). E. Insulin receptor mRNA expression in White adipose 426 
tissue. (n = 7 – 15). Data are presented as mean ± SEM. Vs MC/OC/V (*p < 0.05, **p < 0.01, ***p 427 
< 0.001); vs MC/OHF/V (‡‡p < 0.01); SRT1720-treatment group vs the corresponding VEH 428 
controls  (†p < 0.05, ††p < 0.01, †††p < 0.01). V (VEH), S (SRT1720) 429 
 430 
Figure 3. Adipose tissue analysis. A. H&E staining; B. Cell size analysis; C. mRNA expression. (n 431 
= 6). Data are presented as mean ± SEM. Vs MC/OC/V (**p < 0.01); vs MC/OHF/V (‡p < 0.05); 432 
SRT1720-treatment group vs the corresponding VEH controls (†p < 0.05, ††p < 0.01). V (VEH), S 433 
(SRT1720). 434 
 435 
Figure 4. Liver lipid metabolism. A. Liver Triglyceride level; B. H&E staining; C. Oil Red O 436 
staining and quantitation of lipid droplets; D. Liver mRNA expression of lipid metabolism 437 
regulators. (n = 6). Data are presented as mean ± SEM. Vs MC/OC/V (*p<0.05, **p < 0.01, ***p < 438 
0.001); vs MC/OHF/V (‡‡p < 0.01); SRT1720-treatment group vs the corresponding VEH controls  439 
(†p < 0.05, ††p < 0.01, †††p < 0.01). V (VEH), S (SRT1720). Scale bar = 100 μm. 440 
 441 
Figure 5. Offspring liver oxidative stress, inflammation, fibrogenesis and injury. A. Oxidative 442 
stress markers (RNS: reactive nitrogen species); B. Inflammation, apoptosis and fibrogenesis; C. 443 
Picro-Sirius Red staining; D. Plasma alanine Aminotransferase level. (n = 6). Data are presented as 444 
mean ± SEM. Vs MC/OC/V (*p < 0.05); SRT1720-treatment group vs the corresponding VEH 445 
controls (†p < 0.05). V (VEH), S (SRT1720) 446 





